Loading…
Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage
Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1). Twenty neonatal pigs (weight 1.8 to 2.8 kg...
Saved in:
Published in: | Circulation (New York, N.Y.) N.Y.), 2000-02, Vol.101 (5), p.541-546 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63 |
---|---|
cites | cdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63 |
container_end_page | 546 |
container_issue | 5 |
container_start_page | 541 |
container_title | Circulation (New York, N.Y.) |
container_volume | 101 |
creator | CHAI, P. J NASSAR, R OAKELEY, A. E CRAIG, D. M QUICK, G. JR JAGGERS, J SANDERS, S. P UNGERLEIDER, R. M ANDERSON, P. A. W |
description | Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1).
Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023).
sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome. |
doi_str_mv | 10.1161/01.CIR.101.5.541 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70890379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>53910976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYNY7Lb13ScJIj511iSTj51HWbQWCoIfzyGT3NQp-RiTGWT_e1N3QenT5cDvHO7hIPSKki2lkr4ndLu__bql7Yqt4PQZ2lDBeMdFPzxHG0LI0KmesXN0UetDk7JX4gU6p0RKpgTboN_fcljHANjmOAeIkBZcwMK85NJRPJe8gF0q_gmmLNc4rOn-GpvksDXFTcbieMh-Cuav0a_JLlNO2Jccj0Se1xBzMuWAx8NsasXORHMPV-jMm1Dh5eleoh-fPn7ff-7uvtzc7j_cdZb3fOkGT0BJwuzo1cA9oVKQnR0Vp44CF2CocOCElcwwEJyM3hLliBrNuAPlZH-J3h1zW5NfK9RFx6laCMEkyGvViuwG0quhgW-egA95Lan9phllSu5aeoPIEbIl11rA67lMsZXTlOjHRTShui3SJNVCt0Wa5fUpdx0juP8Mxwka8PYEmGpN8MUkO9V_HJP9MLD-Dy4UlSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212768540</pqid></control><display><type>article</type><title>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</title><source>EZB Electronic Journals Library</source><creator>CHAI, P. J ; NASSAR, R ; OAKELEY, A. E ; CRAIG, D. M ; QUICK, G. JR ; JAGGERS, J ; SANDERS, S. P ; UNGERLEIDER, R. M ; ANDERSON, P. A. W</creator><creatorcontrib>CHAI, P. J ; NASSAR, R ; OAKELEY, A. E ; CRAIG, D. M ; QUICK, G. JR ; JAGGERS, J ; SANDERS, S. P ; UNGERLEIDER, R. M ; ANDERSON, P. A. W</creatorcontrib><description>Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1).
Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023).
sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.101.5.541</identifier><identifier>PMID: 10662752</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Actin Cytoskeleton - chemistry ; Actin Cytoskeleton - drug effects ; Actin Cytoskeleton - physiology ; Anesthesia ; Anesthesia depending on type of surgery ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Biological and medical sciences ; Blood Pressure - drug effects ; Calcium - metabolism ; Cardiopulmonary Bypass - adverse effects ; Heart Diseases - etiology ; Heart Diseases - physiopathology ; Heart Diseases - prevention & control ; Heart Function Tests ; Lung Diseases - etiology ; Lung Diseases - physiopathology ; Lung Diseases - prevention & control ; Medical sciences ; Oxygen - metabolism ; Postoperative Complications - prevention & control ; Protective Agents - therapeutic use ; Protein Conformation ; Receptors, Complement - therapeutic use ; Respiratory Function Tests ; Swine ; Thoracic and cardiovascular surgery. Cardiopulmonary bypass ; Time Factors</subject><ispartof>Circulation (New York, N.Y.), 2000-02, Vol.101 (5), p.541-546</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Feb 8, 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</citedby><cites>FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1263992$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10662752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHAI, P. J</creatorcontrib><creatorcontrib>NASSAR, R</creatorcontrib><creatorcontrib>OAKELEY, A. E</creatorcontrib><creatorcontrib>CRAIG, D. M</creatorcontrib><creatorcontrib>QUICK, G. JR</creatorcontrib><creatorcontrib>JAGGERS, J</creatorcontrib><creatorcontrib>SANDERS, S. P</creatorcontrib><creatorcontrib>UNGERLEIDER, R. M</creatorcontrib><creatorcontrib>ANDERSON, P. A. W</creatorcontrib><title>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1).
Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023).
sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.</description><subject>Actin Cytoskeleton - chemistry</subject><subject>Actin Cytoskeleton - drug effects</subject><subject>Actin Cytoskeleton - physiology</subject><subject>Anesthesia</subject><subject>Anesthesia depending on type of surgery</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium - metabolism</subject><subject>Cardiopulmonary Bypass - adverse effects</subject><subject>Heart Diseases - etiology</subject><subject>Heart Diseases - physiopathology</subject><subject>Heart Diseases - prevention & control</subject><subject>Heart Function Tests</subject><subject>Lung Diseases - etiology</subject><subject>Lung Diseases - physiopathology</subject><subject>Lung Diseases - prevention & control</subject><subject>Medical sciences</subject><subject>Oxygen - metabolism</subject><subject>Postoperative Complications - prevention & control</subject><subject>Protective Agents - therapeutic use</subject><subject>Protein Conformation</subject><subject>Receptors, Complement - therapeutic use</subject><subject>Respiratory Function Tests</subject><subject>Swine</subject><subject>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</subject><subject>Time Factors</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpdkd1rFDEUxYNY7Lb13ScJIj511iSTj51HWbQWCoIfzyGT3NQp-RiTGWT_e1N3QenT5cDvHO7hIPSKki2lkr4ndLu__bql7Yqt4PQZ2lDBeMdFPzxHG0LI0KmesXN0UetDk7JX4gU6p0RKpgTboN_fcljHANjmOAeIkBZcwMK85NJRPJe8gF0q_gmmLNc4rOn-GpvksDXFTcbieMh-Cuav0a_JLlNO2Jccj0Se1xBzMuWAx8NsasXORHMPV-jMm1Dh5eleoh-fPn7ff-7uvtzc7j_cdZb3fOkGT0BJwuzo1cA9oVKQnR0Vp44CF2CocOCElcwwEJyM3hLliBrNuAPlZH-J3h1zW5NfK9RFx6laCMEkyGvViuwG0quhgW-egA95Lan9phllSu5aeoPIEbIl11rA67lMsZXTlOjHRTShui3SJNVCt0Wa5fUpdx0juP8Mxwka8PYEmGpN8MUkO9V_HJP9MLD-Dy4UlSg</recordid><startdate>20000208</startdate><enddate>20000208</enddate><creator>CHAI, P. J</creator><creator>NASSAR, R</creator><creator>OAKELEY, A. E</creator><creator>CRAIG, D. M</creator><creator>QUICK, G. JR</creator><creator>JAGGERS, J</creator><creator>SANDERS, S. P</creator><creator>UNGERLEIDER, R. M</creator><creator>ANDERSON, P. A. W</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20000208</creationdate><title>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</title><author>CHAI, P. J ; NASSAR, R ; OAKELEY, A. E ; CRAIG, D. M ; QUICK, G. JR ; JAGGERS, J ; SANDERS, S. P ; UNGERLEIDER, R. M ; ANDERSON, P. A. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Actin Cytoskeleton - chemistry</topic><topic>Actin Cytoskeleton - drug effects</topic><topic>Actin Cytoskeleton - physiology</topic><topic>Anesthesia</topic><topic>Anesthesia depending on type of surgery</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium - metabolism</topic><topic>Cardiopulmonary Bypass - adverse effects</topic><topic>Heart Diseases - etiology</topic><topic>Heart Diseases - physiopathology</topic><topic>Heart Diseases - prevention & control</topic><topic>Heart Function Tests</topic><topic>Lung Diseases - etiology</topic><topic>Lung Diseases - physiopathology</topic><topic>Lung Diseases - prevention & control</topic><topic>Medical sciences</topic><topic>Oxygen - metabolism</topic><topic>Postoperative Complications - prevention & control</topic><topic>Protective Agents - therapeutic use</topic><topic>Protein Conformation</topic><topic>Receptors, Complement - therapeutic use</topic><topic>Respiratory Function Tests</topic><topic>Swine</topic><topic>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHAI, P. J</creatorcontrib><creatorcontrib>NASSAR, R</creatorcontrib><creatorcontrib>OAKELEY, A. E</creatorcontrib><creatorcontrib>CRAIG, D. M</creatorcontrib><creatorcontrib>QUICK, G. JR</creatorcontrib><creatorcontrib>JAGGERS, J</creatorcontrib><creatorcontrib>SANDERS, S. P</creatorcontrib><creatorcontrib>UNGERLEIDER, R. M</creatorcontrib><creatorcontrib>ANDERSON, P. A. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHAI, P. J</au><au>NASSAR, R</au><au>OAKELEY, A. E</au><au>CRAIG, D. M</au><au>QUICK, G. JR</au><au>JAGGERS, J</au><au>SANDERS, S. P</au><au>UNGERLEIDER, R. M</au><au>ANDERSON, P. A. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2000-02-08</date><risdate>2000</risdate><volume>101</volume><issue>5</issue><spage>541</spage><epage>546</epage><pages>541-546</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1).
Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023).
sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>10662752</pmid><doi>10.1161/01.CIR.101.5.541</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 2000-02, Vol.101 (5), p.541-546 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_70890379 |
source | EZB Electronic Journals Library |
subjects | Actin Cytoskeleton - chemistry Actin Cytoskeleton - drug effects Actin Cytoskeleton - physiology Anesthesia Anesthesia depending on type of surgery Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Biological and medical sciences Blood Pressure - drug effects Calcium - metabolism Cardiopulmonary Bypass - adverse effects Heart Diseases - etiology Heart Diseases - physiopathology Heart Diseases - prevention & control Heart Function Tests Lung Diseases - etiology Lung Diseases - physiopathology Lung Diseases - prevention & control Medical sciences Oxygen - metabolism Postoperative Complications - prevention & control Protective Agents - therapeutic use Protein Conformation Receptors, Complement - therapeutic use Respiratory Function Tests Swine Thoracic and cardiovascular surgery. Cardiopulmonary bypass Time Factors |
title | Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T18%3A17%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20complement%20receptor-1%20protects%20heart,%20lung,%20and%20cardiac%20myofilament%20function%20from%20cardiopulmonary%20bypass%20damage&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=CHAI,%20P.%20J&rft.date=2000-02-08&rft.volume=101&rft.issue=5&rft.spage=541&rft.epage=546&rft.pages=541-546&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.101.5.541&rft_dat=%3Cproquest_cross%3E53910976%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212768540&rft_id=info:pmid/10662752&rfr_iscdi=true |